Brokerages Set InflaRx N.V. (NASDAQ:IFRX) Target Price at $7.00

InflaRx N.V. (NASDAQ:IFRX) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $7.00.

Several brokerages have recently weighed in on IFRX. Cantor Fitzgerald increased their target price on shares of InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Guggenheim reaffirmed a “buy” rating and set a $14.00 price objective on shares of InflaRx in a research note on Tuesday, April 21st. Finally, Zacks Research raised shares of InflaRx from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 27th.

InflaRx Price Performance

NASDAQ IFRX opened at $1.77 on Thursday. InflaRx has a 1 year low of $0.74 and a 1 year high of $2.95. The company has a market capitalization of $127.96 million, a PE ratio of -2.49 and a beta of 2.48. The company has a fifty day moving average of $1.92 and a two-hundred day moving average of $1.52.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. On average, research analysts expect that InflaRx will post -0.29 earnings per share for the current year.

Institutional Trading of InflaRx

Several hedge funds and other institutional investors have recently bought and sold shares of the company. 683 Capital Management LLC boosted its holdings in shares of InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock worth $3,348,000 after purchasing an additional 1,065,000 shares during the last quarter. T3 Companies LLC acquired a new position in shares of InflaRx during the 4th quarter valued at about $294,000. DCF Advisers LLC purchased a new position in shares of InflaRx during the 4th quarter worth about $160,000. Concurrent Investment Advisors LLC increased its position in InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in InflaRx during the fourth quarter worth approximately $104,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.